一次情報の記録
ADMIRATION 第 2 相試験において、中等度から重度の atopic dermatitis に対する bosakitug (ATI-045) は、24 週時の EASI スコアの変化率という主要評価項目とすべての副次評価項目を達成できませんでした。強固な標的エンゲージメントとバイオマーカーのダウンレギュレーションが観察されましたが、抗 TSLP mAb 単独では臨床的有効性を示しませんでした。
EX-99.1 2 acrs-ex99d1.htm EX-99.1 Exhibit 99.1 Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 - - Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4R α Bispecific Antibody ATI-052 - WAYNE, Pa., November 16, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bo